Viridian Therapeutics, Inc.\DE (VRDN) Change in Account Payables (2016 - 2026)

Viridian Therapeutics, Inc.\DE's Change in Account Payables history runs 11 years deep, the most recent figure standing at $4.6 million for Q1 2026.

• On a quarterly basis, Change in Account Payables rose 162.32% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $9.4 million, a 679.09% increase from a year earlier, with the FY2025 full-year figure at $6.6 million, up 9089.04% from the prior year.
• Change in Account Payables advanced to $4.6 million in Q1 2026 per VRDN's latest filing, from -$1.4 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $8.0 million in Q3 2022 and bottomed at -$6.6 million in Q1 2023.
• The 5-year median for Change in Account Payables is $482000.0 (2024), against an average of $623705.9.
• Across the five-year window, Change in Account Payables sank 21541.94% in 2023 and jumped 2812.96% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at $1.7 million in 2022, then tumbled by 186.88% to -$1.5 million in 2023, then tumbled by 158.77% to -$3.9 million in 2024, then jumped by 64.82% to -$1.4 million in 2025, then jumped by 435.51% to $4.6 million in 2026.
• Per Business Quant, the three latest VRDN Change in Account Payables figures stand at $4.6 million (Q1 2026), -$1.4 million (Q4 2025), and $1.5 million (Q3 2025).